|Systematic (IUPAC) name|
|Metabolism||Oxidised in circulation|
|Biological half-life||0.36–8.3 hours|
|CAS Registry Number|
|ATC code||R05 V03|
|Molecular mass||164.181 g/mol|
|(what is this?)|
Mesna (INN) // is an organosulfur compound used as an adjuvant in cancer chemotherapy involving cyclophosphamide and ifosfamide. It is marketed by Baxter as Uromitexan and Mesnex. The name of the substance is an acronym for 2-mercaptoethane sulfonate Na (Na being the chemical symbol for sodium). It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
Mesna is used therapeutically to reduce the incidence of haemorrhagic cystitis and haematuria when a patient receives ifosfamide or cyclophosphamide for cancer chemotherapy. These two anticancer agents, in vivo, may be converted to urotoxic metabolites, such as acrolein.
It is administered intravenously or orally (per mouth). The IV mesna infusions would be given with IV ifosfamide, while oral mesna would be given with oral cyclophosphamide. The oral doses must be double the intravenous (IV) mesna dose due to bioavailability issues. The oral preparation allows patients to leave the hospital sooner, instead of staying four to five days for all the IV mesna infusions.
- "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014.
- "Mistabron Ampoules". South African Electronic Package Inserts. August 1973. Retrieved 2008-08-12.
- Mace JR, Keohan ML, Bernardy H et al. (December 2003). "Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide". Clin. Cancer Res. 9 (16 Pt 1): 5829–34. PMID 14676103.
- Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B (March 2001). "Mesna: a novel renoprotective antioxidant in ischaemic acute renal failure". Nephrol. Dial. Transplant. 16 (3): 542–51. doi:10.1093/ndt/16.3.542. PMID 11239029.